Embedded in the core of all our endeavors lies an unwavering commitment to deliver potent new cancer treatments to patients. Our dedication, evident from the very beginning, has led to a determination to comprehend a fresh therapeutic approach. Our aim is to harness the insights of our scientific founders to create innovative treatments that stimulate the immune system, aiding patients in overcoming their cancer. The therapeutic potential of the inherent immune system, the primary defense against cancer, was not thoroughly comprehended and valued at the time when Irv Weissman and his peers at Stanford University uncovered CD47-SIRP-alpha as a new immune pathway.
Forty Seven
Headquarters
United States of America